China Pharma Inc.
CPHI | AMEX
$0.67
-$0.01 (-1.69%)
Sep 22, 2026, 2:08 PM ET · Market open
Fiscal Year Period Ending | FY 2025 Dec 30, 2025 | FY 2024 Dec 30, 2024 | FY 2023 Dec 30, 2023 | FY 2022 Dec 30, 2022 | FY 2021 Dec 30, 2021 | FY 2020 Dec 30, 2020 |
|---|---|---|---|---|---|---|
Revenue | 4.14M | 4.53M | 7.01M | 8.1M | 9.64M | 10.87M |
Cost of Revenue | 4.28M | 6.51M | 7.29M | 8.6M | 9.29M | 8.91M |
Gross Profit | -131.95K | -1.99M | -281.09K | -493.92K | 349.27K | 1.95M |
Operating Income | -3.09M | -4.59M | -2.75M | -3.55M | -2.86M | -2.58M |
Interest Income | 2K | 6.64K | 6.6K | 10.76K | 3.04K | 5.68K |
Pretax Income | -3.19M | -4.74M | -3.08M | -3.97M | -3.4M | -2.87M |
Net Income | -3.19M | -4.74M | -3.08M | -3.97M | -3.4M | -2.87M |
Selling & General & Admin | 2.83M | 2.31M | 2.25M | 2.96M | 3.15M | 4.04M |
Research & Development | 280.9K | 283.94K | 240.08K | 185.86K | 318.96K | 377.96K |
Other Expenses | -151.56K | 5.7K | -15.76K | -93.85K | -255.22K | 115.19K |
Operating Expenses | 2.96M | 2.6M | 2.47M | 3.06M | 3.21M | 4.53M |
Interest Expense | 102.04K | 154.14K | 333.6K | 434.62K | 542K | 294.16K |
Selling & Marketing Expenses | 375.79K | 528.82K | 780.33K | 1.07M | 1.5M | 2.22M |
Cost & Expenses | 7.23M | 9.12M | 9.76M | 11.65M | 12.5M | 13.44M |
Income Tax Expense | n/a | n/a | n/a | n/a | n/a | n/a |
Shares Outstanding (Basic) | 4.29M | 17.46M | 10.6M | 5.26M | 4.61M | 4.61M |
Shares Outstanding (Diluted) | 4.29M | 17.46M | 10.6M | 5.26M | 4.61M | 4.61M |
EPS (Basic) | -0.74 | -0.27 | -0.29 | -1.94 | -0.85 | -0.72 |
EPS (Diluted) | -0.74 | -0.27 | -0.29 | -1.94 | -0.85 | -0.72 |
EBITDA | -1.51M | -1.96M | 8.44K | -837.69K | 230.35K | 106.85K |
EBIT | -3.09M | -4.58M | -2.75M | -3.54M | -2.86M | -2.57M |
Depreciation & Amortization | 1.58M | 2.62M | 2.75M | 2.7M | 3.09M | 2.68M |
Add to Watchlist
Select watchlists to add or remove CPHI